HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwata, A. Articles by Harlan, J. M. Search for Related Content PubMed PubMed Citation Articles by Iwata, A. Articles by Harlan, J. M.

A Broad-Spectrum Caspase Inhibitor Attenuates Allergic Airway Inflammation in Murine Asthma Model¹

Akiko Iwata^2,*, Kazumi Nishio, Robert K. Winn^*, Emil Y. Chi, William R. Henderson, Jr. and John M. Harlan

Departments of ^* Surgery, Medicine, and Pathology, University of Washington, Seattle, WA 98104

Asthma is characterized by acute and chronic airway inflammation, and the severity of the airway hyperreactivity correlates with the degree of inflammation. Many of the features of lung inflammation observed in human asthma are reproduced in OVA-sensitized/challenged mice. T lymphocytes, particularly Th2 cells, are critically involved in the genesis of the allergic response to inhaled Ag. In addition to antiapoptotic effects, broad-spectrum caspase inhibitors inhibit T cell activation in vitro. We investigated the effect of the broad-spectrum caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk), on airway inflammation in OVA-sensitized/challenged mice. OVA-sensitized mice treated with z-VAD-fmk immediately before allergen challenge showed marked reduction in inflammatory cell infiltration in the airways and pulmonary blood vessels, mucus production, and Th2 cytokine production. We hypothesized that the caspase inhibitor prevented T cell activation, resulting in the reduction of cytokine production and eosinophil infiltration. Treatment with z-VAD-fmk in vivo prevented subsequent T cell activation ex vivo. We propose that caspase inhibitors may offer a novel therapeutic approach to T cell-dependent inflammatory airway diseases.

This article has been cited by other articles:

				C. A. Hudson, G. P. Christophi, R. C. Gruber, J. R. Wilmore, D. A. Lawrence, and P. T. Massa Induction of IL-33 expression and activity in central nervous system glia J. Leukoc. Biol., September 1, 2008; 84(3): 631 - 643. [Abstract] [Full Text] [PDF]

				J. A. Emamaullee, L. Stanton, C. Schur, and A.M. J. Shapiro Caspase Inhibitor Therapy Enhances Marginal Mass Islet Graft Survival and Preserves Long-Term Function in Islet Transplantation Diabetes, May 1, 2007; 56(5): 1289 - 1298. [Abstract] [Full Text] [PDF]

				R. Guo, Y. Wang, A. W. Minto, R. J. Quigg, and P. N. Cunningham Acute Renal Failure in Endotoxemia is Dependent on Caspase Activation J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3093 - 3102. [Abstract] [Full Text] [PDF]

				A. K. Nussbaum and J. L. Whitton The Contraction Phase of Virus-Specific CD8+ T Cells Is Unaffected by a Pan-Caspase Inhibitor J. Immunol., December 1, 2004; 173(11): 6611 - 6618. [Abstract] [Full Text] [PDF]

				T. Krakauer Caspase Inhibitors Attenuate Superantigen-Induced Inflammatory Cytokines, Chemokines, and T-Cell Proliferation Clin. Vaccine Immunol., May 1, 2004; 11(3): 621 - 624. [Abstract] [Full Text] [PDF]